CA2997946A1 - Use of interleukin 2 for treating spondyloarthritis - Google Patents
Use of interleukin 2 for treating spondyloarthritis Download PDFInfo
- Publication number
- CA2997946A1 CA2997946A1 CA2997946A CA2997946A CA2997946A1 CA 2997946 A1 CA2997946 A1 CA 2997946A1 CA 2997946 A CA2997946 A CA 2997946A CA 2997946 A CA2997946 A CA 2997946A CA 2997946 A1 CA2997946 A1 CA 2997946A1
- Authority
- CA
- Canada
- Prior art keywords
- interleukin
- use according
- spondyloarthritis
- months
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 92
- 102000000588 Interleukin-2 Human genes 0.000 title claims abstract description 92
- 201000005671 spondyloarthropathy Diseases 0.000 title claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 238000011418 maintenance treatment Methods 0.000 claims abstract description 6
- 208000024891 symptom Diseases 0.000 claims description 15
- 238000012423 maintenance Methods 0.000 claims description 9
- 208000006820 Arthralgia Diseases 0.000 claims description 7
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
- 206010046851 Uveitis Diseases 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 230000002093 peripheral effect Effects 0.000 description 9
- 210000003289 regulatory T cell Anatomy 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 235000014966 Eragrostis abyssinica Nutrition 0.000 description 7
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 206010003549 asthenia Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 4
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000036314 physical performance Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 208000005801 spondylosis Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000008822 Ankylosis Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000002501 natural regulatory T cell Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 210000003131 sacroiliac joint Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306383.9 | 2015-09-10 | ||
| EP15306383 | 2015-09-10 | ||
| PCT/EP2016/071370 WO2017042370A1 (en) | 2015-09-10 | 2016-09-09 | Use of interleukin 2 for treating spondyloarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2997946A1 true CA2997946A1 (en) | 2017-03-16 |
Family
ID=54145708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2997946A Abandoned CA2997946A1 (en) | 2015-09-10 | 2016-09-09 | Use of interleukin 2 for treating spondyloarthritis |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190060407A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3347036A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018526459A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016319292A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2997946A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017042370A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12020550661A1 (en) | 2017-11-21 | 2021-04-19 | Univ Leland Stanford Junior | Partial agonists of interleukin-2 |
| US11534479B2 (en) | 2018-02-16 | 2022-12-27 | Iltoo Pharma | Use of interleukin 2 for treating Sjögren's syndrome |
| WO2020007937A1 (en) * | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| CA3107461A1 (en) | 2018-08-01 | 2020-02-06 | Taris Biomedical Llc | Methods of treating overactive bladder using trospium |
| WO2021146436A2 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012228418B2 (en) * | 2011-03-11 | 2016-09-29 | Assistance Publique - Hopitaux De Paris | Use of low dose IL-2 for treating autoimmune - related or inflammatory disorders |
| CN104189892A (zh) * | 2014-08-22 | 2014-12-10 | 北京大学人民医院 | 低剂量白细胞介素2在免疫相关性疾病治疗中的应用 |
-
2016
- 2016-09-09 AU AU2016319292A patent/AU2016319292A1/en not_active Abandoned
- 2016-09-09 CA CA2997946A patent/CA2997946A1/en not_active Abandoned
- 2016-09-09 US US15/758,800 patent/US20190060407A1/en not_active Abandoned
- 2016-09-09 WO PCT/EP2016/071370 patent/WO2017042370A1/en not_active Ceased
- 2016-09-09 EP EP16770224.0A patent/EP3347036A1/en not_active Withdrawn
- 2016-09-09 JP JP2018532806A patent/JP2018526459A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3347036A1 (en) | 2018-07-18 |
| US20190060407A1 (en) | 2019-02-28 |
| AU2016319292A1 (en) | 2018-04-12 |
| WO2017042370A1 (en) | 2017-03-16 |
| JP2018526459A (ja) | 2018-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7561893B2 (ja) | 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ－２の使用 | |
| US20210038691A1 (en) | Use of low dose il-2 for treating autoimmune-related or inflammatory | |
| CA2997946A1 (en) | Use of interleukin 2 for treating spondyloarthritis | |
| US11534479B2 (en) | Use of interleukin 2 for treating Sjögren's syndrome | |
| JP2022539785A (ja) | ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途 | |
| US4946674A (en) | Process for treatment of rheumatic diseases | |
| US12329758B2 (en) | Methods for the treatment of psoriatic arthritis | |
| US20180325931A1 (en) | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome | |
| ES2309299T3 (es) | Tratamiento de la artritis reumatoide usando imatinib. | |
| Karanikolas et al. | Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. | |
| WO2020007937A1 (en) | Use of interleukin-2 for treating systemic sclerosis | |
| US20100234277A1 (en) | Coadministration of alpha-fetoprotein and a disease modifying anti-rheumatic drug for treating inflammatory arthritic disease | |
| US20230338356A1 (en) | Treatment of autoimmune skin disease | |
| Opoka-Winiarska et al. | Current indications for the use of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis | |
| US20050147588A1 (en) | Methods for treatment of obesity and for promotion of weight loss | |
| WO2000035472A2 (en) | Cytokine combination therapy | |
| JP5699030B2 (ja) | エタネルセプトを含む線維筋痛症の治療剤 | |
| WO2023114833A1 (en) | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions | |
| Galbizo et al. | Chronic graft-versus-host disease | |
| Williams et al. | Chronic Graft-Versus-Host Disease. | |
| MEMON et al. | EFFICACY OF CYCLOSPORINE IN 36 PATIENTS WITH RHEUMATOID ARTHRITIS | |
| WO2020172238A1 (en) | A method for predicting and monitoring the efficacy of low-dose il-2 and hydroxychloroquine therapy in autoimmune diseases and its long-term use in autoimmune-related conditions | |
| HK1072192B (en) | Treatment of rheumatoid arthritis using imatinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220309 |
|
| FZDE | Discontinued |
Effective date: 20220309 |